Arax Advisory Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $15.7K | Sell |
125
-5
| -4% | -$628 | ﹤0.01% | 1763 |
|
|
2025
Q1 | $14.4K | Sell |
130
-404
| -76% | -$44.7K | ﹤0.01% | 1448 |
|
|
2024
Q4 | $72.9K | Sell |
534
-248
| -32% | -$33.9K | ﹤0.01% | 780 |
|
|
2024
Q3 | $90.1K | Hold |
782
| – | – | 0.01% | 525 |
|
|
2024
Q2 | $108K | Buy |
782
+739
| +1,719% | +$102K | 0.01% | 459 |
|
|
2024
Q1 | $5.93K | Hold |
43
| – | – | ﹤0.01% | 870 |
|
|
2023
Q4 | $5.67K | Sell |
43
-3
| -7% | -$395 | ﹤0.01% | 860 |
|
|
2023
Q3 | $5.18K | Buy |
46
+9
| +24% | +$1.01K | ﹤0.01% | 868 |
|
|
2023
Q2 | $3.49K | Sell |
37
-9
| -20% | -$849 | ﹤0.01% | 934 |
|
|
2023
Q1 | $4.66K | Hold |
46
| – | – | ﹤0.01% | 870 |
|
|
2022
Q4 | $5.49K | Hold |
46
| – | – | ﹤0.01% | 771 |
|
|
2022
Q3 | $5K | Buy |
46
+9
| +24% | +$978 | ﹤0.01% | 811 |
|
|
2022
Q2 | $4K | Hold |
37
| – | – | ﹤0.01% | 833 |
|
|
2022
Q1 | $3K | Buy |
+37
| New | +$3K | ﹤0.01% | 890 |
|